贵州百灵小儿柴桂退热颗粒荣获第二十一届“中国专利优秀奖”
7月15日，国家知识产权局公布了第二十一届中国专利奖授奖的决定。贵州百灵小儿柴桂退热颗粒发明专利“一种用于小儿外感发热的中药制剂及其制备工艺(专利号：ZL200510054694.8)”荣获“中国专利优秀奖”。这是继银丹心脑通软胶囊、咳速停糖浆/胶囊之后，贵州百灵第三次获得这一国家级奖项，彰显了公司突出的产品优势、核心竞争力及品牌影响力。 中国专利奖是国家知识产权局和联合国世界知识产权组织(WIPO)为强化知识产权保护和运用工作导向，加快推进知识产权战略和创新驱动发展战略深入实施而设立。作为中国专门对授予专利权的发明创造给予奖励的政府部门奖，中国专利奖在国内外都具有重要地位和重大影响。
贵州百灵小儿柴桂退热颗粒（4g/袋）属于全国独家规格品种，已被纳入《国家医保目录》，并成功入选《国家基本药物目录》（2018年版）及国家卫生健康委员会“十三五”规划教材《临床常用方剂与中成药》推荐用药等。在新冠肺炎疫情防控中，该产品被列为《贵州省新型冠状病毒肺炎中医药防治参考方案（第二版）》中成药推荐用药。
贵州百灵小儿柴桂退热颗粒是根据《伤寒论》中经典的“柴胡桂枝汤”改良精制而成，组方由柴胡、桂枝、葛根、浮萍、黄岑、白芍、蝉蜕七位药物组成，具有发汗解表、清里退热的功效，用于小儿外感发热、上呼吸道感染等治疗。
作为临床运用多年医保药物，贵州百灵小儿柴桂退热颗粒具有“临床疗效确切、安全性良好、质优价廉”等主要特点，相比于市面上其他同类品种，市场销售价格更为优惠，是老百姓买得起的好药。凭借产品优势及多年市场口碑验证，该产品荣登2019年度中国非处方药产品榜，获得“中成药•儿科感冒咳嗽类”第7名。
近年来，贵州百灵以小儿柴桂退热颗粒、双羊喉痹通颗粒为代表的颗粒剂产品销量保持快速增长，2019年公司颗粒剂产品共计实现销售收入6.6亿元，较去年同期增长16.96%。随着小儿柴桂退热颗粒由处方药转为OTC，该产品市场份额仍有望继续扩大。同时，为满足市场对颗粒剂产品需求，贵州百灵积极开展技改和扩建项目建设。目前，自2018年启动建设的10#楼颗粒剂车间项目已顺利投产运营，可实现10亿袋年产能，为公司近几年增长较快的颗粒剂产品提供充足的产能支持。
作为贵州省新医药产业骨干企业和全国最大的苗药研制生产企业，贵州百灵一贯重视产品研发工作，将其视为推动自身发展的源动力，已建立了较为完善的技术创新体系，持续强化科技成果转化落地。截至2019年底，公司有效专利数为101件，其中PCT7件，国内发明61件，外观设计7件，实用新型26件。公司生产的17个苗药品种全部拥有发明专利。
创新研发是医药企业立身之本，也是成就企业核心竞争力，参与市场竞争的关键。未来，贵州百灵将不断加大创新研发投入，继续稳步推进新药研发创新工作，同时着力于产品结构调整，注重市场潜力大及研发壁垒高的产品开发，凭借自身对技术创新的不懈追求，为人民群众生命健康贡献更多智慧。
{"weixin":{"label":"微信","name":"weixin","selected":true,"value":true,"sortid":"1","shareid":"weixin","sharetitle":"分享到微信","event":"shareToWeiXin","lang":"shareWeb_WeiXin"},"copy":{"label":"复制网址","name":"copy","selected":true,"value":true,"sortid":"2","shareid":"copy","sharetitle":"复制网址","event":"copy_url","lang":"shareWeb_Copy"},"qq":{"label":"QQ好友","name":"qq","selected":true,"value":false,"sortid":"1","shareid":"qq","sharetitle":"分享到QQ","event":"shareToQQ","lang":"shareWeb_QQ"},"sina_weibo":{"label":"新浪微博","name":"sina_weibo","selected":true,"value":true,"sortid":"4","shareid":"sina_weibo","sharetitle":"分享到新浪微博","event":"shareToSinaWB","lang":"shareWeb_SinaWeiBo"},"qq_zone":{"label":"QQ空间","name":"qq_zone","selected":true,"value":true,"sortid":"5","shareid":"qq_zone","sharetitle":"分享到QQ空间","event":"shareToQzone","lang":"shareWeb_QQZone"},"renren":{"label":"人人网","name":"renren","selected":true,"value":true,"sortid":"7","shareid":"renren","sharetitle":"分享到人人网","event":"shareToRenren","lang":"shareWeb_RenRen"},"douban":{"label":"豆瓣网","name":"douban","selected":true,"value":true,"sortid":"8","shareid":"douban","sharetitle":"分享到豆瓣网","event":"shareToDouban","lang":"shareWeb_DouBan"},"baidu_tieba":{"label":"百度贴吧","name":"baidu_tieba","selected":true,"value":true,"sortid":"10","shareid":"baidu_tieba","sharetitle":"分享到百度贴吧","event":"shareToTieba","lang":"shareWeb_TieBa"},"Facebook":{"label":"Facebook","name":"Facebook","selected":true,"value":true,"sortid":"11","shareid":"Facebook","sharetitle":"分享到FaceBook","event":"shareToFacebook","lang":"shareWeb_Facebook"},"Twitter":{"label":"Twitter","name":"Twitter","selected":true,"value":true,"sortid":"12","shareid":"Twitter","sharetitle":"分享到Twitter","event":"shareToTwitter","lang":"shareWeb_Twitter"},"LinkedIn":{"label":"LinkedIn","name":"LinkedIn","selected":true,"value":true,"sortid":"13","shareid":"LinkedIn","sharetitle":"分享到linkedIn","event":"shareToLinkedin","lang":"shareWeb_Linkedin"},"whatsapp":{"label":"whatsapp","name":"whatsapp","selected":true,"value":true,"sortid":"15","shareid":"whatsapp","sharetitle":"分享到whatsapp","event":"shareToWhatsapp","lang":"shareWeb_whatsapp"},"line":{"label":"line","name":"line","selected":true,"value":true,"sortid":"15","shareid":"line","sharetitle":"分享到line","event":"shareToLine","lang":"shareWeb_line"},"qq_weibo":{"label":"腾讯微博","name":"qq_weibo","selected":true,"value":true,"sortid":"3","shareid":"qq_weibo","sharetitle":"分享到腾讯微博","event":"shareToQQwb","lang":"shareWeb_QQWeiBo"},"peopleBlog":{"label":"人民微博","name":"propleBlog","selected":true,"value":true,"sortid":"14","shareid":"propleBlog","sharetitle":"分享到人民微博","event":"shareToPeopleBlog","lang":"shareWeb_peopleBlog"}}
